Ensitrelyir Fumaric Acid in Patients with SARS-CoV-2: 1

A Retrospective Chart Review 2

- Masaya Yamato,¹ Masahiro Kinoshita,² Shogo Miyazawa,³ Masayuki Seki,¹ Tomoki Mizuno,¹ 3
- 4 Takuhiro Sonoyama⁴
- 5

6 Affiliations:

- 7 ¹Department of General Internal Medicine and Infectious Diseases, Rinku General Medical Center,
- 8 Izumisano, Japan
- 9 ²Medical Affairs, Shionogi & Co., Ltd., Osaka, Japan
- 10 ³Data Science Department, Shionogi & Co., Ltd., Osaka, Japan
- 11 ⁴Medical Science Department, Shionogi & Co., Ltd., Osaka, Japan

12

- 13 Correspondence: Takuhiro Sonoyama
- 14 Vice President, Medical Science Department, Shionogi & Co., Ltd.
- 15 3-1-8, Doshomachi, Chuo-ku, Osaka 541-0045, Japan
- 16 e-mail: takuhiro.sonoyama@shionogi.co.jp
- 17 Alternate corresponding author: Masahiro Kinoshita
- 18 Global Medical Affairs Lead, Medical Affairs, Shionogi & Co., Ltd.
- 19 3-1-8, Doshomachi, Chuo-ku, Osaka 541-0045, Japan
- 20 e-mail: masahiro.kinoshita@shionogi.co.jp

21

22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 Word Count: 3261

- 24 Tables/Figures: 3/1
- 25 Supplementary Tables/Figures: 1/0

27 ABSTRACT

45

28 Introduction: Antivirals with differing mechanisms of action are needed for COVID-19 treatment; 29 remdesivir is mainly used in hospitalized patients, but additional antivirals are needed in this setting. 30 Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022, 31 based on evidence of rapid symptom resolution in non-hospitalized patients, but confirmation of its 32 efficacy in hospitalized patients is lacking. 33 Case presentations: This case series reports outcomes for all patients who received ensitrelyir whilst 34 hospitalized with SARS-CoV-2 infection at Rinku General Medical Center, Japan (November 2022– 35 April 2023). Thirty-two hospitalized patients received five days of ensitrelvir treatment (375/125 mg). 36 Mean age was 73.5 years and most patients had mild COVID-19. Patients exhibited various 37 underlying diseases, most commonly hypertension (78.1%) and chronic kidney disease (25.0%). 38 Seven (21.9%) patients were on hemodialysis. The most common concomitant medications were 39 antihypertensives (59.4%) and corticosteroids (31.2%); two (6.3%) patients were being treated with 40 rituximab; 27 (84.4%) patients had viral persistence following pre-treatment remdesivir failure. 41 Following ensitrelvir treatment, all patients experienced clinical improvement as assessed by the 42 investigator. No ICU admissions or deaths due to COVID-19 occurred. Viral clearance was recorded in 43 18 (56.3%) patients by day 5 and 25 (78.1%) patients at final measurement. No new safety signals 44 were observed.

46 CoV-2 in a real-world setting. Most patients experienced persistent viral shedding despite pre-47 treatment with antivirals, and most were considered high-risk due to underlying conditions. Despite 48 this, no patients experienced progression of COVID-19 to severe or critical disease, including those 49 who failed prior remdesivir treatment. The antiviral activity of ensitrelvir demonstrated here 50 indicates it is a viable treatment option for SARS-CoV-2 infection in this setting.

Discussion: This case series represents ensitrely r clinical efficacy in hospitalized patients with SARS-

- 51 *Conclusion:* Ensitrelvir was associated with potent antiviral activity and positive clinical outcomes in
- 52 high-risk, hospitalized patients with various comorbidities.
- 53 Trial Registration: UMIN000051300
- 54
- 55 Keywords: SARS-CoV-2; Ensitrelvir; COVID-19; Viral load; Viral persistence; Remdesivir-failure

56

- 57 Key Summary Points
- 58 Why carry out this study?
- Real-world evidence of ensitrelvir for the treatment of COVID-19, especially in inpatient settings,
- 60 is required.
- This was a retrospective cohort analysis, consisting of 32 high-risk hospitalized patients with a
- 62 range of disease severities and comorbidities, including patients who had experienced remdesivir
- 63 treatment failure.
- 64 What was learned from the study?
- All patients experienced clinical improvement following ensitrelvir treatment, without any

66 worsening COVID-19.

- Viral clearance was documented in 78.1% of patients at final viral measurement.
- No new safety signals of ensitrelvir were observed in this analysis.

70 **INTRODUCTION**

71 The first cases of the novel coronavirus disease (COVID-19) caused by severe acute respiratory 72 syndrome coronavirus 2 (SARS-CoV-2) infection were identified in Wuhan City, Hubei Province, China, 73 in December 2019[1]. Following the global spread of infections, the World Health Organization 74 (WHO) declared COVID-19 a pandemic in March 2020[2]. As of June 2023, there have been 75 ~768,000,000 confirmed cases and ~6,900,000 deaths reported to the WHO[3], including 76 ~33,800,000 cases and ~75,000 deaths reported in Japan[3]. Since its identification as a variant of 77 concern (VOC) in November 2021, the Omicron variant and its sublineages have been the dominant 78 SARS-CoV-2 variants worldwide, responsible for the vast majority of reported cases[4-6]. Compared 79 with previous VOC's (particularly Delta), the Omicron variant is associated with reduced symptom 80 severity[7-10], but increased transmission[11-13] and immune evasion[14, 15]. Whilst Omicron 81 infection generally leads to less severe outcomes than Delta, its increased transmissibility led to a 82 significant healthcare burden globally; Japan's sixth, seventh, and eighth COVID-19 waves, caused by 83 Omicron infection, were associated with the highest levels of COVID-19 cases and deaths reported 84 since the start of the pandemic[3]. 85 Booster vaccines and hybrid immunity (immunity developed from both vaccination and previous 86 SARS-CoV-2 infection) consistently provide high protection against Omicron-related severe disease, 87 but their effectiveness wanes over time[16-18]; furthermore, many monoclonal antibodies 88 previously used to treat people infected with SARS-CoV-2 have demonstrated reduced neutralization 89 and binding affinity to the Omicron variant and its sublineages[19, 20]. Patients with severe 90 comorbidities are still at increased risk of poor outcomes when infected with the Omicron variant, 91 including progression to severe disease and death[21-23]. Additionally, patients with severe 92 comorbidity burden and immunocompromised patients, including those on hemodialysis[24], are 93 likely to be at more risk from prolonged viral shedding and viral persistence[25-29]. This can increase 94 the overall disease burden for these patients, for example by interfering with the management of 95 underlying diseases in patients with hematological malignancies[30, 31]. An antiviral agent that can

96 rapidly reduce SARS-CoV-2 virus levels and prevent viral persistence would therefore be a beneficial
97 treatment option for this patient population.

98 Remdesivir is an intravenously administered antiviral, which is indicated in Japan for the treatment of 99 COVID-19 in patients: with oxygen saturation \leq 94%; who require supplementary oxygen; or with 100 pneumonia because of SARS-CoV-2[32]. Nirmatrelvir/ritonavir (Paxlovid®) and molnupiravir 101 (Lagevrio[®]) are oral antivirals for the treatment of COVID-19; both have received emergency 102 authorization in many countries, including Japan, for the treatment of patients infected with SARS-103 CoV-2, with risk factors for severe disease. Nirmatrelvir/ritonavir also received the United States Food and Drug Administration's full approval in May 2023[33]. In clinical trials in non-hospitalized 104 105 patients, both drugs demonstrated significantly lower rates of hospitalization or death versus 106 placebo[34, 35], and reductions in SARS-CoV-2 viral ribose nucleic acid by day 5[34, 36]. However, 107 approval for both drugs was based on clinical trials in unvaccinated individuals, before Omicron 108 became the predominant SARS-CoV-2 strain[34, 35]. Since then, nirmatrelvir/ritonavir failed to meet 109 the primary endpoint of self-reported, sustained alleviation of all symptoms in non-hospitalized 110 patients at low risk of progressing to severe disease in the phase 2/3 EPIC-SR study[37]. 111 Ensitrelvir fumaric acid (Xocova[®]) is an oral antiviral, developed by Shionogi & Co., Ltd. for the 112 treatment of infection caused by SARS-CoV-2. Ensitrelvir acts through the same mechanism as nirmatrelvir, inhibiting the 3C-like protease, which is essential for viral replication and processing of 113 114 the polyprotein encoded by the SARS-CoV-2 gene[38]. In the recently reported phase 3 trial 115 SCORPIO-SR, ensittelvir met the primary endpoint and demonstrated a significantly shorter time to 116 resolution of five symptoms typical of Omicron infection compared with placebo (-24.3 hours; 95% 117 CI – 78.7 to 11.7; p = 0.04) in patients aged 12–69 with mild-to-moderate COVID-19[39]. Based on 118 these data, as well as efficacy from the phase 2b part[40], ensitrelvir received emergency 119 authorization in Japan for the treatment of SARS-CoV-2 infection. In addition, ensitrelvir has 120 demonstrated rapid and significant reductions in SARS-CoV-2 viral RNA: a 30-fold reduction in mean

- 121 viral RNA levels compared with placebo at day 4 [mean difference –1.47 log₁₀ tissue culture
- 122 infectious dose (TCID₅₀)/mL] was recorded in the SCORPIO-SR trial[39]. Ensitrelvir treatment in
- hospitalized patients is being investigated in the ongoing STRIVE study[41].
- 124 Despite positive outcomes reported in clinical trials, evidence on the efficacy and safety of ensitrelvir
- in clinical practice is limited. The aim of this retrospective chart review was to evaluate the treatment
- 126 status, including patient background and treatment outcomes, of patients treated with ensitrelyir in
- 127 Japan, November 2022 and April 2023, immediately after emergency approval of ensitrelvir in
- 128 November 2022 and when the Omicron variant was dominant.

130 METHODS

131 Study Design/Period

- 132 This was a single center, retrospective chart review of patients prescribed ensitrelyir for the
- 133 treatment of SARS-CoV-2 infection, from November 2022 to April 2023 in the Rinku General Medical
- 134 Center. Ensitrelvir (375/125 mg) was dosed orally once a day for five days, where 375 mg was dosed
- 135 on day 0 as a loading dose and 125 mg was dosed on days 1–4 as a maintenance dose.

136 Patient Population

- 137 All patients who received ensitrelvir between November 2022 and April 2023 were included in the
- 138 study. Only patients for whom the following data were obtained were included in the analytical
- population (Fig. 1): start and end date of ensitrelvir treatment; a SARS-CoV-2 positive test result;
- 140 SARS-CoV-2 virus test results [antigen test, reverse transcription polymerase chain reaction (RT-PCR)]
- 141 after starting administration of ensitrelvir; clinical outcomes of SARS-CoV-2 infection. Patients were
- 142 excluded from the analytical population if they were not treated in accordance with ensitrelyir
- 143 prescribing instruction or if they refused to participate in the study. This current paper reports results
- 144 for hospitalized patients only.

145 Data Collection

- 146 Data were collected using electronic medical records of the Rinku General Medical Center.
- 147 Pseudonymized information was aggregated and analyzed as anonymized information using an
- anonymization tool (CoNaxs[®], Conax Automomation Sdn. Bhd).
- 149 The study collected general information of patients including gender, age, date of COVID-19 onset,
- underlying disease/complications, pre-treatment and post-treatment for SARS-CoV-2 infection,
- 151 concomitant medications, previous SARS-CoV-2 infection history, and SARS-CoV-2 vaccination status
- 152 (number of vaccinations and time of last vaccination).

153 Treatment information collected included ensitrelvir administration start and end date, prior

154 therapies, and concomitant drug use.

155	Clinical information was also collected, including imaging findings, body temperature (axillary),
156	clinical signs and symptoms, level of consciousness, and oxygen saturation. Disease severity at the
157	start of ensitrelvir administration was classified by investigator according to the Japanese guideline
158	on COVID-19 treatment (Supplementary Table 1)[42]. The presence/absence of pneumonia, oxygen
159	administration (including flow rate), mechanical ventilation, and intensive care unit (ICU)
160	management were also recorded, as well as the implementation status of dialysis. Finally, clinical
161	outcomes of SARS-CoV-2 infection and any adverse events (AEs) related to ensitrelvir were recorded.
162	Virological information collected consisted of SARS-CoV-2 virus test results (antigen test, RT-PCR).
163	Quantitative antigen level in nasopharyngeal swab was assessed using Lumipulse $^{ extsf{R}}$ (Fujirevio, Tokyo,
164	Japan), with a maximum viral antigen level of 5,000 pg/mL and a cut-off value of 1.34 pg/mL. It has
165	previously been reported that a cut-off value of 89.73 pg/mL corresponds to a cycle threshold (Ct)
166	value of \geq 35 by quantitative PCR[43]. When estimating the infectivity of SARS-CoV-2, a Ct value \geq 35
167	is often used as a marker for non-infectious viral levels[44-46]. Therefore, we defined viral clearance
168	as an antigen level of < 89.73 pg/mL. Viral rebound was defined as an increase of antigen level of ≧
169	89.73 pg/mL after viral clearance.

170 Endpoints

The primary endpoint of the study was viral antigen or PCR results (quantitative or qualitative results) at each time point from the start of administration to 10 days after the end of ensitrelvir administration. The secondary endpoint was investigator-assessed improvement at the end of ensitrelvir treatment (day 4 following administration of ensitrelvir). Exploratory endpoints included presence or absence of hospitalization; ICU admission; and death up to 14 days after the start of

administration. Safety of ensitrelyir treatment was also assessed, by recording any treatment-related

177 AEs. No statistical analyses were performed as this was a descriptive study.

178

179 RESULTS

180 Patient disposition and baseline characteristics

181 Fifty-two patients with SARS-CoV-2 infection who received ensitrelvir were identified between

182 November 2022 and April 2023 at Rinku General Medical Center. One was excluded due to co-usage

183 of contraindicated drugs. In total, 32 of the included patients were hospitalized and 19 were

184 outpatients (Fig. 1). Here we report the outcomes for the 32 hospitalized patients only, all of whom

185 completed 5 days of ensitrelvir treatment. Outcomes for the 19 outpatients will be reported in detail

186 separately, due to the limited follow-up data available.

187 Within the hospitalized analytical population (N = 32), the average age was 73.5 years old, and 25

188 (78.1%) patients were age 65 years and older (Table 1). At the start of ensitrelvir treatment, 21/32

189 (65.6%) patients had mild COVID-19 disease severity; four (12.5%) had moderate I severity; and

seven (21.9%) had moderate II severity (Table 1), according to the Japanese guideline. All seven

191 patients with moderate II disease were on inhaled oxygen therapy and eight patients (25%) had

evidence of pneumonia at the start of ensitrelvir treatment (two with moderate I disease and six

193 with moderate II) (Table 1). Prior antiviral therapy had been administered to 29/32 (90.6%) patients,

194 including all 11 patients with moderate I or II disease (Table 1). The most common prior therapy was

remdesivir [27/32 (84.4%)], either delivered as monotherapy [*n* = 24 (75%)] or alongside

196 casirivimab/imdevimab [n = 3 (9.4%)], and 21/27 (77.8%) patients received ≥ 3 days of remdesivir

- 197 (mean 6.6 days, range 3–22 days). One patient (3.1%) received casirivimab/imdevimab monotherapy
- and one patient (3.1%) received molnupiravir monotherapy. Patients were switched to ensitrelvir

199 based on investigator assessments of clinical and virological status: either clinical symptoms were not 200

A higher proportion of patients with moderate I or II disease [2/4 (50.0%) and 4/7 (57.1%), 201

resolved, or viral clearance was required for further medical procedures.

- 202 respectively] were unvaccinated for SARS-CoV-2, compared with patients with mild disease [5/21
- 203 (23.8%)] (Table 1). The most common concomitant medications were antihypertensives [19 (59.4%)]
- 204 and corticosteroids [10 (31.2%)]. One (3.1%) patient received immunosuppressants (cyclosporine),
- 205 and 18 (58.1%) received precautioned medicines (medicines included in the "Precautions for
- 206 concomitant use" section of the prescribing instructions due to potential interactions with
- 207 ensitrelvir). Two (6.3%) patients received rituximab in the days before ensitrelvir treatment (days -49
- 208 and -16, respectively). Seven (22.6%) patients received hemodialysis. Patients exhibited a wide range
- 209 of underlying diseases: the most common underlying comorbidity was hypertension [25/32 (78.1%)]
- 210 followed by chronic kidney disease [8/32 (25.0%)], cerebral infarction [7/32 (21.9%)], diabetes
- 211 mellites [7/32 (21.9%)], and dyslipidemia [7 (21.9%)]. Ten patients (31.3%) had malignant tumor.
- 212 Individual patient demographics and characteristics can be seen in Table 2.
- 213 Virology outcomes

214 All 32 patients received the full five days of ensitrelvir treatment (days 0–4) (Table 3). Viral clearance (antigen level < 89.73 pg/mL) was observed by day 5 in 18/32 (56.3%) patients and antigen level 215 216 below lower the limit of quantification (cut-off level: < 1.34 pg/mL) was observed in 5/32 (15.6%) 217 patients by day 5. Viral clearance was observed at final measurement in 25/32 (78.1%) patients and a 218 final antigen quantification measurement of < 1.34 pg/mL was observed in 20/32 (62.5%) patients. 219 Viral rebound after end of ensitrelvir treatment was observed in four (12.5%) patients: two (Patient 9 220 and Patient 14) had neither rebound of clinical symptoms, nor additional antiviral treatment; one 221 (Patient 25) had no rebound of clinical symptoms but received remdesivir from day 8 to day 13; and 222 one (Patient 28) experienced transient increase of body temperature \geq 37.5 degree Celsius at the 223 time of viral rebound and received remdesivir treatment from day 11 to day 15, with viral clearance

224	observed on day 14 and day 15. No disease progression was observed in these four cases. In a
225	subgroup analysis of 21 patients who switched to ensitrelyir following failure of \geq 3 days remdesivir
226	treatment or remdesivir plus casirivimab/imdevimab, 13/21 (61.9%) achieved viral clearance by day
227	5. Patient 18 did not achieve viral clearance and received remdesivir between day 7 and day 11, as
228	well as meropenem for aspirational pneumonia with onset after completion of ensitrelvir treatment.
229	Secondary clinical outcomes and exploratory endpoints
230 231	All 32 patients achieved clinical improvement as assessed by the investigator at the end of ensitrelvir
232	therapy (day 4 following administration of ensitrelvir). Six (18.8%) patients (Patient 2, 4, 17, 18, 27
233	and 28) experienced a transient increase of body temperature to ≧37.5 degree Celsius after end of
234	ensitrelvir treatment. No patients were admitted to the ICU and no patients died up to 14 days
235	following administration of ensitrelvir. In addition, no patients progressed to severe disease over the
236	course of the study. Sixteen patients were discharged from hospital before day 14, and fifteen were
237	discharged after day 14 (range: day 14–77). One patient (Patient 24) died on day 59; this death was
238	considered unrelated to COVID-19 and due to an underlying comorbidity of ANCA-associated
239	vasculitis.
240	Safety
241	No ensitrelvir treatment-related AEs were observed, and ensitrelvir treatment was not discontinued
242	for any patient.
243	
244	DISCUSSION
245	Here we report the first case series for hospitalized patients treated with ensitrelvir for SARS-CoV-2

246 infection following emergency approval in November 2022. Whilst ensitrelvir has demonstrated rapid

- alleviation of symptoms in its clinical studies[39, 40, 47], the efficacy of ensitrelvir in patients
- 248 hospitalized with COVID-19 is unclear. Also, the current Japanese guideline on COVID-19 treatment

249 recommends ensitrelvir for the treatment of mild/moderate I disease only, regardless of the 250 presence of any risk factors for severe disease[42]. This case series represents clinical efficacy of 251 ensitrelvir treatment in hospitalized patients with SARS-CoV-2 in a real-world setting, and has 252 demonstrated successful ensited view in this population, including patients with moderate II 253 disease severity. This study included a high-risk patient population who had severe comorbidities and 254 an average age of 73.5 years. Despite this, all patients achieved clinical improvement as assessed by 255 the investigator at day 4 and no cases of ICU admission or death occurred over 14 days, indicating 256 that ensitrelvir successfully prevented progression to severe disease in this high-risk group. 257 In this case series, ensitrelvir also demonstrated antiviral activity; viral clearance (defined in the 258 methods section) was achieved by day 5 in 18/32 (56.3%) patients. Viral persistence is an unmet 259 need for patients with COVID-19, particularly for immunocompromised patients [25, 26] and patients 260 with comorbidities[28, 29] for whom COVID-19 infection is associated with negative outcomes[21-23, 261 48, 49]. Prolonged SARS-CoV-2 infection has been linked with rapid viral evolution[50, 51], and it has 262 also been hypothesized that viral persistence may increase the likelihood of long COVID[52-54]. 263 Furthermore, reductions in viral titer and load following antiviral therapy have been linked to 264 reduction in mortality rates and improved symptom resolution[34, 55, 56] and may decrease the 265 potential for SARS-CoV-2 transmission[55]. Therefore, it is important to reduce the viral load of SARS-266 CoV-2, both in the short and long term.

267 Whilst ensitrelvir in hospitalized patients is being investigated in the ongoing STRIVE study[41], the 268 results of this case series align with reported clinical trial data for ensitrelvir in non-hospitalized 269 patients. In the randomized, placebo-controlled, phase 3 SCORPIO-SR study, reduction from baseline 270 in SARS-CoV-2 viral RNA on day 4 was significantly greater with ensitrelvir compared with placebo 271 (least-squares mean [log₁₀ TCID₅₀/mL]: -2.48 versus -1.01, *p* < .001)[39]. Information on viral RNA 272 reduction in hospitalized patients for other oral antivirals is limited, but a recent phase 3 study of 273 nirmatrelvir/ritonavir in hospitalized adult patients with severe comorbidities reported no significant

difference in duration of SARS–CoV-2 RNA clearance compared with placebo[57]. Not all patients
achieved viral clearance following ensitrelvir treatment in this case series, but all patients improved
clinically as determined by the investigator at day 4.

277 Of note, most patients (27/32) in this case series were treated with ensitrelvir after failure of 278 remdesivir treatment (remdesivir alone or remdesivir plus casirivimab/imdevimab). Of these 279 patients, 21 switched to ensitrely following failure of \geq 3 days remdesivir treatment. All patients in 280 this subgroup achieved investigator-judged clinical improvement at day 4, suggesting ensitrelvir is 281 effective even when received \geq 3 days after onset of infection, an outcome that has not yet been demonstrated in clinical trials[58]. These findings may mean that ensitrelvir could provide clinical 282 benefit to patients even when it is administered at a delayed phase of the disease with persistent 283 284 viral infection.

285 Currently available treatments, remdesivir and nirmatrelvir are not recommended for patients with

eGFR <30mL/min. In this case series, seven patients received hemodialysis alongside ensitrelyir

treatment, all of whom clinically improved, with no adverse event. Of the seven who received

hemodialysis, three reported viral clearance by day 5 and five were discharged from hospital by day

14. This suggests that ensitrelyir may be a viable treatment option for these patients.

290 This retrospective chart review has several limitations. It was a single center study, with a relatively 291 small patient population and, given the nature of the study, there was no control group. As such, it is 292 difficult to draw conclusions on the comparative efficacy and safety of ensitrely ir from this study 293 alone. Secondly, due to the retrospective nature of the study, the evaluation and timings for each 294 outcome do not necessarily match between patients. Not all patients had an antigen quantitative 295 measurement taken after end of ensitrelvir treatment, nor did patients receive them on the same 296 days. Additionally, although these were hospitalized patients, and so represent those impacted 297 heavily by infection, most patients had mild disease severity on commencement of ensitrelyir. There 298 were less than 10 patients in each of the moderate I and moderate II disease groups, limiting the

299 conclusions we can draw from these populations. Finally, there were no pre-specified or standardized 300 criteria for: patients switching to ensitrelyir from remdesivir; the evaluation of clinical outcomes 301 following ensitrelvir treatment; or discharge from hospital following ensitrelvir treatment. All 302 decisions were based on the clinical judgement of the investigator. 303 The main strength of this study is that it reflects real-world use of ensitrelvir and outcomes in 304 patients with a wide range of comorbidities. The study was also conducted after emergency approval 305 of ensitrelvir in November 2022, during the Omicron era, representing the efficacy of ensitrelvir 306 against this persisting variant. 307 Whilst ensitrelyir demonstrated efficacy in the majority of patients, there were cases where 308 ensitrelvir failed to achieve viral clearance and cases of viral rebound and/or transient increase of 309 body temperature. Three patients received post-antiviral treatment (remdesivir). There are several 310 reports about rebound of SARS-CoV-2 and symptoms with nirmatrelvir-ritonavir and molnupiravir in 311 hospitalized patients with COVID-19 [59], as well as non-hospitalized patients [60]. In this case series, 312 only one patient developed both viral rebound and a transient increase in body temperature, but did 313 not develop any other symptoms at the time of viral rebound. Overall, in this case series, viral 314 rebound was not correlated with transient increase of body temperature, and did not lead to serious clinical outcomes, which is consistent with previous reports with other SARS-CoV-2 antivirals [59, 61]. 315 316 Further investigation of antiviral and clinical efficacy of ensitrelvir in hospitalized patients is 317 warranted.

318

319 CONCLUSIONS

Ensitrelvir showed potent antiviral activity and was associated with positive clinical outcomes in a generally high-risk, hospitalized, elderly patient population with mild–moderate COVID-19 infection, including in those with a variety of comorbidities. In the majority of cases, ensitrelvir demonstrated potent antiviral activity despite previous remdesivir treatment failure and clinical improvement was

- 324 reported in all patients. Of note, no patients progressed to severe or critical diseases of COVID-19 in
- 325 this generally high-risk population. This case series adds to the growing clinical information
- 326 supporting the efficacy and safety of ensitrelvir for the treatment of patients infected with SARS-CoV-
- 327 2, including those hospitalized with a range of high-risk factors, even when treatment was delayed
- 328 beyond 72 hours from disease onset.

330 ACKNOWLEDGEMENTS

- 331 The authors would like to thank the patients and their families. Rinku General Medical Center used
- 332 SIMPRESEARCH[®] as a data tabulation tool, and we would like to thank the SIMPRESEARCH[®]
- developer, 4DIN Ltd. The authors would also like to thank Tsukasa Horiyama for their contribution to

334 manuscript development.

335

Funding. The implementation of this research was funded by Shionogi & Co., Ltd., Osaka, Japan.

337 Shionogi & Co., Ltd. Also took in charge all costs associated with the development and publication of

- this manuscript, including the journal's Rapid Service Fee.
- 339 *Medical Writing and Editorial Assistance.*
- Editorial assistance in the preparation of this manuscript, under the direction of the authors, was
 provided by Ian McAllister, BSc, of Ashfield MedComms, an Inizio Company, funded by Shionogi &
 Co., Ltd., and complied with Good Publication Practice (GPP) guidelines (DeTora LM, et al. Ann Intern
 Med 2022;175:1298–1304).

344 Author Contributions. Masaya Yamato was responsible for research planning, study conception and 345 design, acquisition of data, quality assurance, interpretation of results, drafting the article, and 346 revising the article critically for important intellectual content. Masayuki Seki and Tomoki Mizuno 347 were responsible for acquisition of data, quality assurance, drafting the article, and revising the article critically for important intellectual content. Masahiro Kinoshita, Shogo Miyazawa and Tomoki 348 Sonoyama were responsible for research planning, interpretation of results, drafting the article, and 349 350 revising the article critically for important intellectual content. All authors gave final approval before 351 submission.

Disclosures. Masaya Yamato has received lecture fees from, and serves as an advisor for, Shionogi &
 Co., Ltd.. Masahiro Kinoshita, Shogo Miyazawa and Takuhiro Sonoyama are employees of Shionogi &

- Co., Ltd.. Masayuki Seki and Tomoki Mizuno have nothing to disclose. This study was supported by
 Shionogi & Co., Ltd. In the form of all costs associated with the development and publication of this
 manuscript.
- 357 Compliance with Ethics Guidelines. The study was conducted in accordance with the Declaration of
- 358 Helsinki, and approved by the Rinku General Medical Center Clinical Research Ethics Committee (2-
- 23 Rinku Oraikita, Izumisano City 598-0048; protocol ID: 2023FY-I-001; date of approval 18 May
- 360 2023). Patient consent was acquired using an opt-out procedure and no data were included that
- 361 would allow identification of individual patients. This study was registered in UMIN Clinical Trials
- 362 Registry (study ID: UMIN000051300).
- 363 Data Availability. All associated data are published within the main body of the manuscript and
- 364 supplementary materials.

366 References

367 368	1.	Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and
369		Control. J Clin Med. 2020;9(4). <u>https://doi.org/10.3390/jcm9041225</u> .
370	2.	WHO. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11
371		March 2020. https://www.who.int/director-general/speeches/detail/who-director-general-s-
372		opening-remarks-at-the-media-briefing-on-covid-1911-march-2020. Accessed Aug 9 2023.
373	3.	WHO. WHO Coronavirus (COVID-19) Dashboard. https://covid19.who.int/ . Accessed Aug 9,
374		2023.
375	4.	WHO. One year since the emergence of COVID-19 virus variant Omicron.
376		https://www.who.int/news-room/feature-stories/detail/one-year-since-the-emergence-of-
377		omicron#:~:text=It%20was%2026%20November%202021,of%20the%20COVID%2D19%20pa
378		ndemic. Accessed Aug 9, 2023.
379	5.	Fan Y, Li X, Zhang L, Wan S, Zhang L, Zhou F. SARS-CoV-2 Omicron variant: recent progress and
380		future perspectives. Signal Transduct Target Ther. 2022;7(1):141.
381		https://doi.org/10.1038/s41392-022-00997-x.
382	6.	Tian D, Sun Y, Xu H, Ye Q. The emergence and epidemic characteristics of the highly mutated
383		SARS-CoV-2 Omicron variant. J Med Virol. 2022;94(6):2376–83.
384		https://doi.org/10.1002/jmv.27643.
385	7.	Esper FP, Adhikari TM, Tu ZJ, et al. Alpha to Omicron: Disease Severity and Clinical Outcomes
386		of Major SARS-CoV-2 Variants. J Infect Dis. 2023;227(3):344–52.
387		https://doi.org/10.1093/infdis/jiac411.
388	8.	Hyams C, Challen R, Marlow R, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2)
389		SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United
390		Kingdom. Lancet Reg Health Eur. 2023;25:100556.
391		https://doi.org/10.1016/j.lanepe.2022.100556.
392	9.	Petrone D, Mateo-Urdiales A, Sacco C, et al. Reduction of the risk of severe COVID-19 due to
393		Omicron compared to Delta variant in Italy (November 2021 - February 2022). Int J Infect Dis.
394		2023;129:135–41. <u>https://doi.org/10.1016/j.ijid.2023.01.027</u> .
395	10.	Strasser ZH, Greifer N, Hadavand A, Murphy SN, Estiri H. Estimates of SARS-CoV-2 Omicron
396		BA.2 Subvariant Severity in New England. JAMA Netw Open. 2022;5(10):e2238354.
397		https://doi.org/10.1001/jamanetworkopen.2022.38354.
398	11.	Backer JA, Eggink D, Andeweg SP, et al. Shorter serial intervals in SARS-CoV-2 cases with
399		Omicron BA.1 variant compared with Delta variant, the Netherlands, 13 to 26 December
400		2021. Euro Surveill. 2022;27(6). <u>https://doi.org/10.2807/1560-7917.Es.2022.27.6.2200042</u> .
401	12.	Del Águila-Mejía J, Wallmann R, Calvo-Montes J, Rodríguez-Lozano J, Valle-Madrazo T,
402		Aginagalde-Llorente A. Secondary Attack Rate, Transmission and Incubation Periods, and
403		Serial Interval of SARS-CoV-2 Omicron Variant, Spain. Emerg Infect Dis. 2022;28(6):1224–8.
404		https://doi.org/10.3201/eid2806.220158.
405	13.	Madewell ZJ, Yang Y, Longini IM, Jr., Halloran ME, Dean NE. Household secondary attack rates
406		of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-
407		analysis. JAMA Netw Open. 2022(5):e229317.
408		https://doi.org/10.1001/jamanetworkopen.2022.9317.
409	14.	Rössler A, Riepler L, Bante D, von Laer D, Kimpel J. SARS-CoV-2 Omicron Variant
410		Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med.
411		2022;386(7):698–700. <u>https://doi.org/10.1056/NEJMc2119236</u> .
412	15.	Willett BJ, Grove J, MacLean OA, et al. SARS-CoV-2 Omicron is an immune escape variant
413		with an altered cell entry pathway. Nat Microbiol. 2022;7(8):1161–79.
414		https://doi.org/10.1038/s41564-022-01143-7.

415	16.	Bobrovitz N, Ware H, Ma X, et al. Protective effectiveness of previous SARS-CoV-2 infection
416		and hybrid immunity against the omicron variant and severe disease: a systematic review
417		and meta-regression. Lancet Infect Dis. 2023;23(5):556–67. https://doi.org/10.1016/s1473-
418		3099(22)00801-5.
419	17.	Lin DY, Xu Y, Gu Y, et al. Effectiveness of Bivalent Boosters against Severe Omicron Infection. N
420		Engl J Med. 2023;388(8):764–6. https://doi.org/10.1056/NEJMc2215471.
421	18.	Solante R, Alvarez-Moreno C, Burhan E, et al. Expert review of global real-world data on
422		COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of
423		the pandemic. Expert Rev Vaccines. 2023:22(1):1–16.
424		https://doi.org/10.1080/14760584.2023.2143347
425	19.	Imai M. Ito M. Kiso M. et al. Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1
426		and XBB. N Engl J Med. 2023:388(1):89–91. https://doi.org/10.1056/NEJMc2214302.
427	20.	McCallum M. Czudnochowski N. Rosen LE. et al. Structural basis of SARS-CoV-2 Omicron
428		immune evasion and recentor engagement. Science, 2022;375(6583):864–8.
429		https://doi.org/10.1126/science.abn8652
430	21	Cheong HH. Sig FL Chan CC et al. Clinical characteristics of COVID-19 natients infected by the
431	21.	Omicron variants in Macao, China: A cross-sectional study. Health Sci Rep. 2023;6(7):e1361
431		https://doi.org/10.1002/bsr2.1361
133	 <i> </i>	Khadela A. Soni S. Megha K. Bhagat S. Chavda VP. A Beview on the Impact of the SARS-CoV-2
433	22.	Omicron Subvariant on Elderly Datients with Diverse Co-Morbidities 2022:2(2):138-57
434		https://doi.org/10.3290/biologics2020008
435	22	Manchanda V, Mitra S, Rafique L, et al. Is Omicron really mild? – Comparative analysis of
430	23.	compendities and disease outcomes associated with SAPS-CoV-2 Omicron (B 1 1 520) and
437		Delta (B 1 617 2) variants Indian I Med Microbiol: 2022:45:100201
430		bttps://doi.org/10.1016/j.jimph.2022.100201
459	24	Alfana C. Marici N. Farri C. at al. Drolanged BT DCB test pacifivity in hamodialysis patients
440	24.	with COVID 10, Bon Bonlaco Thor 2022:0(1):25, https://doi.org/10.1186/c41100.022.00487
441		with COVID-19. Rell Replace Their 2025,9(1).55. <u>https://doi.org/10.1180/541100-025-00487-</u>
442	25	y. Disverti V. Salta Alajandra S. Haidar C. Immunocompromised Patients with Protracted
443	25.	COVID 10: a Deview of "Long Dereistors" Curr Transplant Den, 2022;0(4):200, 19
444		COVID-19: a Review of Long Persisters . Curr transplant Rep. 2022;9(4):209–18.
445	26	$\frac{\text{NLDS:}/(\text{dol.org}/10.100//S404/2-022-00385-y}{\text{Dispersive}}$
446	26.	D'Abramo A, Vita S, Nicastri E. The unmet need for COVID-19 treatment in
447		Immunocompromised patients. BVIC Infect DIs. 2022;22(1):930.
448	27	<u>https://doi.org/10.1186/s128/9-022-0/918-x</u> .
449	27.	Stein SR, Ramelli SC, Grazioli A, et al. SARS-CoV-2 infection and persistence in the human
450		body and brain at autopsy. Nature. 2022;612(7941):758–63.
451	20	<u>https://doi.org/10.1038/s41586-022-05542-y</u> .
452	28.	Pei L, Chen Y, Zheng X, et al. Comorbidities prolonged viral shedding of patients infected with
453		SARS-CoV-2 omicron variant in Shanghai: A multi-center, retrospective, observational study. J
454		Infect Public Health. 2023;16(2):182–9. <u>https://doi.org/10.1016/j.jiph.2022.12.003</u> .
455	29.	Wang M, Mi H, Li N, et al. Association between the overall burden of comorbidity and Ct
456		values among the older patients with Omicron infection: Mediated by inflammation. Front
457		Immunol. 2023;14:11145044. <u>https://doi.org/10.3389/fimmu.2023.1145044</u> .
458	30.	Marangoni D, Antonello RM, Coppi M, et al. Combination regimen of nirmatrelvir/ritonavir
459		and molnupiravir for the treatment of persistent SARS-CoV-2 infection: A case report and a
460		scoping review of the literature. Int J Infect Dis. 2023;133:53–6.
461		https://doi.org/10.1016/j.ijid.2023.04.412.
462	31.	Arcani R, Colle J, Cauchois R, et al. Clinical characteristics and outcomes of patients with
463		haematologic malignancies and COVID-19 suggest that prolonged SARS-CoV-2 carriage is an
464		important issue. Ann Hematol. 2021;100(11):2799–803. <u>https://doi.org/10.1007/s00277-</u>
465		<u>021-04656-z</u> .

466 467	32.	Tsuzuki S, Hayakawa K, Uemura Y, et al. Effectiveness of remdesivir in hospitalized nonsevere patients with COVID-19 in Japan: A large observational study using the COVID-19 Registry
468		Japan. Int J Infect Dis. 2022;118:119–25. <u>https://doi.org/10.1016/j.ijid.2022.02.039</u> .
469	33.	Harris E. FDA Grants Full Approval to Paxlovid, COVID-19 Antiviral Treatment. Jama.
470		2023;329(24):2118. <u>https://doi.org/10.1001/jama.2023.9925</u> .
471	34.	Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk,
472		Nonhospitalized Adults with Covid-19. N Engl J Med. 2022;386(15):1397–408.
473		https://doi.org/10.1056/NEJMoa2118542.
474	35.	Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of
475		Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022;386(6):509–20.
476		https://doi.org/10.1056/NEJMoa2116044.
477	36.	Fischer WA, 2nd, Eron JJ, Jr., Holman W, et al. A phase 2a clinical trial of molnupiravir in
478		patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of
479		infectious virus. Sci Transl Med. 2022;14(628):eabl7430.
480		https://doi.org/10.1126/scitransImed.abl7430
481	37.	Pfizer. Pfizer Reports Additional Data on PAXLOVID™ Supporting Upcoming New Drug
482		Application Submission to U.S. FDA. 2022. https://www.pfizer.com/news/press-
483		release/press-release-detail/pfizer-announces-additional-phase-23-study-results. Accessed
484		Aug 8, 2023.
485	38.	Shimizu R, Sonoyama T, Fukuhara T, Kuwata A, Matsuo Y, Kubota R. Safety, Tolerability, and
486		Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL
487		Protease Inhibitor, in Healthy Adults. Antimicrob Agents Chemother. 2022;66(10):e0063222.
488		https://doi.org/10.1128/aac.00632-22.
489	39.	Yotsuyanagi H, Ohmagari N, Doi Y, et al. Efficacy and Safety of 5-Day Oral Ensitrelvir for
490		Patients With Mild-to-Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial. 2023.
491		https://doi.org/10.1101/2023.07.11.23292264.
492	40.	Mukae H, Yotsuyanagi H, Ohmagari N, et al. Efficacy and Safety of Ensitrelvir in Patients With
493		Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-
494		Controlled, Phase 2/3 Study. Clin Infect Dis. 2023;76(8):1403–11.
495		https://doi.org/10.1093/cid/ciac933
496	41.	ClinicalTrials.gov. Strategies and Treatments for Respiratory Infections & Amp; Viral
497		Emergencies (STRIVE): Shionogi Protease Inhibitor.
498		https://classic.clinicaltrials.gov/ct2/show/NCT05605093?id=NCT05605093&draw=2&rank=1
499		&load=cart. Accessed Aug 7, 2023.
500	42.	Ministry of Health LaW, Japan. New Coronavirus Infectious Disease (COVID-19) Medical
501		Treatment Guide Version 9.0. Ministry of Health LaW. 2023
502		https://www.mhlw.go.jp/content/000936655.pdf. Accessed Aug 7, 2023.
503	43.	Kase F, Ota T, Ota H, et al. Negative confirmation and infectivity estimation by quantitative
504		antigen test of COVID-19 (Japanese language). Jpn J of Med Tech. 2022;71(2):250–6,
505		https://www.jstage.jst.go.jp/article/jamt/71/2/71_21-85/_article/-char/en.
506	44.	Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral Cultures for Coronavirus Disease 2019
507		Infectivity Assessment: A Systematic Review. Clin Infect Dis. 2021;73(11):e3884–e99.
508		https://doi.org/10.1093/cid/ciaa1764.
509	45.	Singanayagam A, Patel M, Charlett A, et al. Duration of infectiousness and correlation with
510		RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020. Euro
511		Surveill. 2020;25(32). <u>https://doi.org/10.2807/1560-7917.Es.2020.25.32.2001483</u> .
512	46.	Zhuang X, Zheng Y, Wei S, et al. Can the nucleic acid Ct value of discharged patients infected
513		with SARS-CoV-2 Omicron variant be 35?A retrospective study on fluctuation of nucleic acid
514		Ct values in SNIEC mobile cabin hospital. Front Cell Infect Microbiol. 2022;12:1059880.
515		https://doi.org/10.3389/fcimb.2022.1059880.

516 517 518 519	47.	Mukae H, Yotsuyanagi H, Ohmagari N, et al. A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to- Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part. Antimicrob Agents Chemother. 2022;66(10):e0069722. <u>https://doi.org/10.1128/aac.00697-</u>
520		<u>22</u> .
521	48.	Baek MS, Lee MT, Kim WY, Choi JC, Jung SY. COVID-19-related outcomes in
522		immunocompromised patients: A nationwide study in Korea. PLoS One.
523		2021;16(10):e0257641. <u>https://doi.org/10.1371/journal.pone.0257641</u> .
524	49.	Belsky JA, Tullius BP, Lamb MG, Sayegh R, Stanek JR, Auletta JJ. COVID-19 in
525		immunocompromised patients: A systematic review of cancer, hematopoietic cell and solid
526		organ transplant patients. J Infect. 2021;82(3):329–38.
527		https://doi.org/10.1016/j.jinf.2021.01.022.
528	50.	Hettle D, Hutchings S, Muir P, Moran E. Persistent SARS-CoV-2 infection in
529		immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study
530		and literature review. Clin Infect Pract. 2022;16:100210.
531		https://doi.org/10.1016/j.clinpr.2022.100210.
532	51.	Kemp SA, Collier DA, Datir RP, et al. SARS-CoV-2 evolution during treatment of chronic
533		infection. Nature. 2021;592(7853):277–82. <u>https://doi.org/10.1038/s41586-021-03291-y</u> .
534	52.	Buonsenso D, Piazza M, Boner AL, Bellanti JA. Long COVID: A proposed hypothesis-driven
535		model of viral persistence for the pathophysiology of the syndrome. Allergy Asthma Proc.
536		2022;43(3):187–93. <u>https://doi.org/10.2500/aap.2022.43.220018</u> .
537	53.	Chen B, Julg B, Mohandas S, Bradfute SB. Viral persistence, reactivation, and mechanisms of
538		long COVID. Elife. 2023;12:e86015. <u>https://doi.org/10.7554/eLife.86015</u> .
539	54.	Yang C, Zhao H, Espín E, Tebbutt SJ. Association of SARS-CoV-2 infection and persistence with
540		long COVID. Lancet Respir Med. 2023;11(6):504–6. <u>https://doi.org/10.1016/s2213-</u>
541		<u>2600(23)00142-x</u> .
542	55.	Huang C, Lu TL, Lin L. Real-World Clinical Outcomes of Molnupiravir for the Treatment of Mild
543		to Moderate COVID-19 in Adult Patients during the Dominance of the Omicron Variant: A
544		Meta-Analysis. Antibiotics (Basel). 2023;12(2). <u>https://doi.org/10.3390/antibiotics12020393</u> .
545	56.	Lee E, Park S, Choi JP, et al. Short-Term Effectiveness of Oral Nirmatrelvir/Ritonavir Against
546		the SARS-CoV-2 Omicron Variant and Culture-Positive Viral Shedding. J Korean Med Sci.
547		2023;38(8):e59. https://doi.org/10.3346/jkms.2023.38.e59.
548	57.	Liu J, Pan X, Zhang S, et al. Efficacy and safety of Paxlovid in severe adult patients with SARS-
549		Cov-2 infection: a multicenter randomized controlled study. Lancet Reg Health West Pac.
550		2023;33:100694. <u>https://doi.org/10.1016/j.lanwpc.2023.100694</u> .
551	58.	Yotsuyanagi H, Ohmagari N, Doi Y, et al. A phase 2/3 study of S-217622 in participants with
552		SARS-CoV-2 infection (Phase 3 part). Medicine (Baltimore). 2023;102(8):e33024.
553		<u>https://doi.org/10.1097/md.00000000033024</u> .
554	59.	Wong CKH, Lau KTK, Au ICH, et al. Viral burden rebound in hospitalised patients with COVID-
555		19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
556		Lancet Infect Dis. 2023;23(6):683-95. <u>https://doi.org/10.1016/S1473-3099(22)00873-8</u> .
557	60.	CDC. Interim Clinical Considerations for COVID-19 Treatment in Outpatients.
558		https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/outpatient-treatment-
559		overview.html. Accessed Aug 17, 2023.
560	61.	Anderson AS, Caubel P, Rusnak JM, Investigators E-HT. Nirmatrelvir-ritonavir and viral load
561		rebound in Covid-19. N Engl J Med. 2022;387(11):1047-9.
562		<u>nπps://doi.org/10.1056/NEJMc2205944</u> .
563		

565 Figure legends

566 Fig. 1 Patient disposition flowchart



567

568

569

ſ

	Overall		Disease severity	,	
Baseline characteristics ^a	(N = 32)	Mild (<i>n</i> = 21)	Moderate I (n = 4)	Moderate II (<i>n</i> = 7)	
Sex				·	
Male	18 (56.3)	9 (42.9)	3 (75.0)	6 (85.7)	
Age, yr	73.5 ± 10.9	75.9 ± 9.0	70.8 ± 9.1	67.9 ± 15.4	
Age groups				1	
20–64	7 (21.9)	2 (9.5)	1 (25.0)	4 (57.1)	
65–74	9 (28.1)	6 (28.6)	2 (50.0)	1 (14.3)	
75+	16 (50.0)	13 (61.9)	1 (25.0)	2 (28.6)	
Pre-treatment for SARS-CoV-2 infect	tion (day –2 to da	iy 0)			
Remdesivir	24 (75.0)	16 (76.2)	3 (75.0)	5 (71.4)	
Casirivimab/imdevimab	1 (3.1)	1 (4.8)	0 (0.0)	0 (0.0)	
Molnupiravir	1 (3.1)	0 (0.0)	1 (25.0)	0 (0.0)	
Remdesivir +	3 (9.4)	1 (4.8)	0 (0.0)	2 (28.6)	
casirivimab/imdevimab	3 (9 /)	3 (1/1 3)	0 (0 0)	0 (0 0)	
SAPS CoV 2 vaccination status	3 (9.4)	5 (14.5)	0 (0.0)	0 (0.0)	
Voc	21 (65 6)	16 (76 2)	2 (50.0)	2 (12 0)	
Number of vaccination docos	21 (05.0)	10 (70.2)	2 (50.0)	5 (42.9)	
	11 (24 4)	F (22.0)	2 (50.0)	4 (57.4)	
0	11 (34.4)	5 (23.8)	2 (50.0)	4 (57.1)	
2	3 (9.4)	2 (9.5)	0 (0.0)	1 (14.3)	
3	4 (12.5)	3 (14.3)	0 (0.0)	1 (14.3)	
4	8 (25.0)	6 (28.6)	2 (50.0)	0 (0.0)	
5	6 (18.8)	5 (23.8)	0 (0.0)	1 (14.3)	
Pneumonia (day –2 to day 0)	8 (25.0)	0 (0.0)	2 (50.0)	6 ^b (85.7)	
Concomitant medications (days 0–4)		1		
Any concomitant medication	31 (96.9)	20 (95.2)	4 (100.0)	7 (100.0)	
Diabetes medication	3 (9.4)	1 (4.8)	0 (0.0)	2 (28.6)	
Antihypertensives	19 (59.4)	10 (47.6)	3 (75.0)	6 (85.7)	
Antineoplastic agents	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	
Immunosuppressents	1 (3.1)	1 (4.8)	0 (0.0)	0 (0.0)	
Corticosteroids for systemic use	10 (31.2)	6 (28.6)	1 (25.0)	3 (42.9)	
Precautioned medicine ^c	19 (59.4)	12 (57.1)	2 (50.0)	5 (71.4)	
Hemodialysis	7 (21.9)	2 (9.5)	2 (50.0)	3 (42.9)	

571 SD standard deviation, yr year

- ^aData are presented as n (%), or mean ± SD
- 573 ^bIncluding two patients with aspiration pneumonia
- ^cMedicines included in the "Precautions for concomitant use" section of the prescribing instructions
- 575 due to potential interactions with ensitrelvir

576

Patient	Disease	Sex	Age	Number	Prior
	severitv		(Range)	of	SARS-CoV-2 treatment
			(- 0-7	vaccinatio	
				ns	
1	Mild	54	90.94		Pomdosivir ^c
1	IVIIIU Modorato I		80-84 65 60	5	Remdesivir
2	Mederate II		70.74	4 F	Reindesivir
3	Nild		70-74	2 2	Refficesivir
4 5	Modorato II	Г	00-04	2	Romdosivir ^c
5	Nild		90-94 75 70	0	Demdesivir
0	IVIIId		75-79	0	Remdesivir
/	IVIIIU	г г	50-54	2	Remdesivir
8	IVIIId	F	70-74	0	Remdesivir ²
9- 10 ^h	IVIIId	F	75-79	0	Remdesivir ²
10°	Noderate I	F	60-64	0	Woinupiravir
11	Mild	F	80-84	5	Remdesivir
12	Mild	M	75-79	4	Remdesivir ^c
13	Moderate II	F	50-54	3	Remdesivir
14	Moderate II	M	80-84	2	Remdesivir ^c
15	Mild	М	75-79	0	
16	Mild	F	65-69	0	Remdesivir ^c
17	Moderate I	М	81-84	4	Remdesivir ^c
18	Mild	F	75-79	3	Remdesivir ^c
19	Mild	F	70-74	4	Remdesivir
20	Mild	М	55-59	4	
21	Mild	F	80-84	4	Remdesivir ^c
22	Mild	М	80-84	3	Remdesivir ^c
23	Moderate II	М	60-64	0	Remdesivir
24	Mild	F	80-84	4	Remdesivir ^c + casirivimab/imdevimab
25	Moderate II	М	55-59	0	Remdesivir + casirivimab/imdevimab
26	Mild	М	70-74	5	Remdesivir ^c
27	Mild	F	90-94	5	Remdesivir ^c
28	Mild	М	70-74	5	Casirivimab/imdevimab
29	Moderate II	М	55-59	0	Remdesivir + casirivimab/imdevimab
30	Moderate I	М	70-74	0	Remdesivir
31	Mild	М	75-79	3	Remdesivir ^c
32	Mild	F	70-74	4	Remdesivir ^c

577 ANCA anti-neutrophil cytoplasmic antibody, BSI bloodstream infection, F female, LOS length of stay,

- 578 M male
- ^aPatient received rituximab at day –49
- 580 ^bPatient received rituximab at day –16

^cPatient received \geq 3 days of remdesivir 581

Table 3 Virology outcomes

		Quantitative viral antigen (pg/mL)													
Patient					Days	from st	tart of	ensitre	elvir ad	minist	ration				
	Day –1 and Day –2	Day 0	Day 1	Day 2	Day 3	Day 4 (EOT)	Day 5	Day 6	Day 7	Day 8	Day 9	Day 10	Day 11	Day 12	Day 13
1	5000	5000		571.44			21.75	18.67	9.43	2.81	0.06	4.79	0.01	0.10	
2	206.25	3429.86	235.08	10.35	1.06	0.95									
3	5000		5000			113.88		0.01							
4	255.09	5000			36.55		25.72	1.61	0.30	0.01					
5	5000	5000		5000	5000	5000				1233.07	494.52		254.76	8.67	44.64
6	5000	5000		1394.43		39.12	43.49	46.30		28.65	0.83	0.89			
7		5000		1676.19					27.73						
8	5000	2728.74	3736.13	142.46		13.50	0.30								
9	5000	5000		2587.88		4.77	1210.73		5000	5000	5000				
10		1227.48		182.59	200.71										
11	5000	5000	5000		1086.83	4091.46			16.27	11.83	3.76	1.73	0.01		
12	5000			1.04	0.11										
13	5000		5000			0.75									
14	5000	5000			87.07	25.39	8.50	6.81	7.94	94.59	0.14	2.29	0.05	1.73	0.57
15		5000			5000		665.36		352.02			8.56	1.30	4.21	0.01
16	5000	5000		53.22			2.10	0.62							
17	5000	5000			537.86		84.40	7.89	43.06	3.56	2.08	0.01	0.06		
18	4328.71	5000		5000			2468.05		5000		3637.23			114.93	12.95
19	5000			344.33											
20		5000ª			5000	97.79		344.12	5000				4664.69		
21	1727.71	2393.09		1354.45			2.51	1.61	1.05	2.59	1.03	0.01			
22	5000		5000			7.42	8.09	1.97	4.39	0.71	2.78	0.67	1.72	0.08	0.24
23		88.50	2.89	0.09											
24	5000	5000			223.72		2.37	8.01	5.99	41.02		1.23	0.01		
25	5000		267.69		38.25				84.65	301			38.23	2.40	8.13
26	1305.00	5000			1021.42				19.95	1.89	0.57	0.24			
27	5000			1767.49	274.52	245.85	147.76	111.48			3.44	6.81	1.92	1.15	0.56

28		PCR Ct 16.6	5000			168.50		86.65	1.39	14.97	6.59	496.04	
29	1635.16		115.32		1463.78		41.1						
30	5000		1125.20										
31	5000	5000		5000		1330.12							
32	5000	5000		1292.38			63.29	9.86	11.31	1.56	0.01		

582 Ct cycle threshold, EOT end of treatment, PCR polymerase chain reaction

583 ^aPCR positive at day 0

Patients received ensitrelvir on days 0–4. Shading represents days the patient was hospitalized 584